Germany-based medical device company specialising in innovative epidermal radioisotope therapies OncoBeta announced on Friday that it has expanded its Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy with the Bolzano Hospital being the latest to come on board.
The company claims that this marks a significant advancement in the availability of non-melanoma skin cancer (NMSC) treatment options within the country.
Presently, Rhenium-SCT is offered in Germany, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. It will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.
Shannon D. Brown III, OncoBeta CCO, said, 'While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption.'
Magellan Health launches Teen Mental Wellbeing app powered by BeMe
Azenta names new president and CEO
PHC announces launch of LiCellMo live cell metabolic analyzer targeting CGT advancements
Expanse Medical names new chief executive officer and FlowPhysix board member
ClariMed opens new Leeds, UK office
Qaelon Medical names new chief executive officer
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy